Professor Peter Sandercock
Emeritus Professor of Medical Neurology

- Centre for Clinical Brain Sciences
Contact details
- Tel: 0131 537 2082
- Email: peter.sandercock@ed.ac.uk
Background
Studied Medicine at the University of Oxford, and undertook my postgraduate clinical training in Stoke-on-Trent, Manchester, Oxford and Liverpool, followed by a visiting academic fellowship at McMaster University Canada. My initial research was on the epidemiology of stroke in Oxfordshire, and in clinical trials of stroke prevention.
I set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke from 1991-1997.19,453 patients were recruited within 48 hours of stroke onset from 467 hospitals in 37 countries. I am the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with 3035 patients.
My main academic activities are teaching, preparing educational maetrials on stroke for the World Stroke Organisation and contribting to clinical trial research governance though membership or Chairmanship of Trial Steering Committes and Trial data Monitoring Committees.
Qualifications
MA, DM
Responsibilities & affiliations
Member of the Board of Directors World Stroke Organisation. Commissioning Editor for the World Stroke Academy.
Research summary
My research covers treatment and prevention of stroke and seeks to identify which interventions are effective, which are not, and which are worth testing in large scale trials. I now spend much of my time either supporting fellow scientist in doing their own clinical trials, looking to improve patient care or teaching and training young researchers in how to do this type of scientific work.
The main focus of my present research is to further explore the effects of intravenous thrombolytic therapy in acute ischaemic stroke in the IST-3 study and other similar trials.
Research activities
-
How can the World Stroke Organization (WSO) optimize education in stroke medicine around the world? Report of the 2018 WSO Global Stroke Stakeholder Workshop
In:
International Journal of Stroke
DOI: https://doi.org/10.1177/1747493019874726
Contribution to journal › Comment/debate (E-pub ahead of print) -
Fluoxetine and Fractures After Stroke : Exploratory Analyses From the FOCUS Trial
In:
Stroke
DOI: https://doi.org/10.1161/STROKEAHA.119.026639
Contribution to journal › Article (Published) -
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases : subgroup analyses of the RESTART randomised, open-label trial
(10 pages)
In:
Lancet Neurology, vol. 18, no. 7, pp. 643-652
DOI: https://doi.org/10.1016/S1474-4422(19)30184-X
Contribution to journal › Article (Published) -
The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage : statistical analysis plan for a randomised controlled trial
In:
Trials, vol. 20, no. 1, pp. 183
DOI: https://doi.org/10.1186/s13063-019-3270-2
Contribution to journal › Article (Published) -
Clinical diagnosis of TIA or minor stroke and prognosis in patients with neurological symptoms: : A rapid access clinic cohort
In:
PLoS ONE, vol. 14, no. 3
DOI: https://doi.org/10.1371/journal.pone.0210452
Contribution to journal › Article (Published)